
usd pm et
summari develop proprietari product use cardiologist physician heart surgeon
angioplasti heart surgeri procedur
price-to-earnings oper ep
risk assess reflect lead posit
vital market -- develop proprietari product
design enabl heart rest heal recov
improv blood flow coronari arteri howev
note highli innov competit marketplac
jan ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
fy expect sale rise
million driven continu sale
follow fy sale growth
million estim earli
market penetr rate still low
estim patient
alon compani also plenti
opportun growth abroad germani
japan key near-term growth target
germani japan import
wide accept product
two countri like lead rapid adopt
surround region view
octob provid impella
heart treatment first patient japan
second largest medic devic market
world expect japan revenu grow
fy million continu
roll devic japanes hospit
june product
avail heart hospit japan
expect fy oper margin
vs fy fy
invest expans continu pay
mostli off-set temporarili weak revenu
believ trade fair
valu especi share plummet
august earn announc
lower full-year outlook
custom confus regard
fda warn letter earli fda letter
warn increas mortal risk small
popul patient unfortun
health care provid media outlet
wrong interpret fda letter
broader product recal hurt sale
result like fall significantli short initi
investor expect still see strength
long-term potenti unless recent
cut guidanc reflect concern
risk target price recommend
unforeseen competit overestim
size end market
particularli newer market
target base
multipl ep
estim lower-end
three-year rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead provid temporari mechan circulatori support
devic develop manufactur market proprietari product design enabl
heart rest heal recov improv blood flow coronari arteri end-organ and/or
temporarili perform pump function heart compani product use cardiac
catheter lab cath lab intervent cardiologist electrophysiolog lab hybrid lab
heart surgeri suit heart surgeon physician might use devic patient
need hemodynam support angioplasti heart surgeri procedur
primari product impella product portfolio includ impella impella cp impella
rp impella ld impella product pipelin includ impella impella ecp impella
btr product servic revenu near futur impella devic
work expand usag awar impella product
one recent fda-approv product impella rp heart pump indic
provid temporari right ventricular support day certain patient develop acut right
heart failur decompens follow left ventricular assist devic implant myocardi infarct
heart transplant open-heart surgeri impella rp heart pump percutan temporari
ventricular support devic fda-approv safe effect right heart failur
market profil accord aha heart diseas stroke statist updat report
coronari heart diseas account approxim death
condit coronari arteri caus reduc blood flow insuffici oxygen deliveri
affect portion heart lead acut myocardi infarct ami commonli known heart
attack may lead heart failur condit heart unabl pump enough blood
bodi major organ
competit among provid treatment fail heart intens subject rapid
technolog chang evolv industri requir standard present futur
product could render obsolet uneconom result technolog advanc one
present futur competitor therapi includ drug therapi must
continu develop commerci new product technolog remain competit
cardiovascular medic technolog industri believ compet primarili basi
clinic superior support extens data innov featur enhanc patient benefit
product perform eas use reliabl
heart replac devic research effort canada europ japan
addit sever compani includ
terumo heart geting maquet cardiovascular sever
early-stag compani develop heart assist product includ implant left ventricular
assist devic miniatur rotari ventricular assist devic directli indirectli compet
major develop februari fda sent letter health care provid regard
increas mortal risk patient receiv abmd impella rp product fda later clarifi may
lower surviv rate impella rp specif patient consid salvag
patient patient standard therapi fail unfortun health care
provid media outlet wrong interpret initi fda letter product recal hurt
earli sale divert manag attent also subsequ clarifi shortli
februari fda letter increas mortal rate specif salvag patient recoveri
financi trend revenu grew fy fy reflect
five-year compound annual growth rate compound-annual-growth-rate -- one highest growth rate medic
equip suppli industri five-year ep compound-annual-growth-rate even higher ep fy
vs fy fy histor debt cash flow
grow free cash flow defin cash flow oper less capit expenditur grew
fy fy fy think financi sound
posit like remain way forese futur
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
bullish sinc octob technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d septemb
vs increas valu
 composit index
vs declin
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
maintain ep post dec-q ep vs
miss estim sale rose near expect driven
growth impella heart pump revenu robust increas
relat intern impella sale gross margin contract
basi point due less favor sale mix manufactur capac expans
danver aachen germani japan continu grow incred
pace believ key growth driver wide accept product
nation like lead rapid adopt surround region given
among fastest grow medic devic compani expect multipl
remain elev level forese futur kevin huang cfa angelo
et cfra reiter hold opinion share inc
maintain target price above-p
ep estim multipl near averag
three-year rang sep-q ep vs
higher estim rais ep
maintain ep sep-q sale increas
million compris growth impella heart pump revenu
million growth outsid impella revenu million
achiev oper margin quarter
increas primarili due higher sale volum
nation cardiogen shock initi ncsi present data show
improv cardiogen shock surviv rate patient follow ncsi
protocol includ impella use survivor
discharg home nativ heart compar year surviv
rate /kevin huang cfa
analyst research note compani news
pm et cfra keep strong buy opinion share inc
keep target base
ep estim sep-q ep vs consensu
expect rais ep
share surg today low expect head quarter sep-q
revenu increas yoy million revenu grew
million intern revenu increas million
oper margin improv mar-q
prior-year quarter announc introduc recent approv
impella limit basi meanwhil continu
success launch smartassist platform although strateg
action invest global commerci team may provid immedi
benefit continu think make right move establish
impella product global standard care certain type compromis
et cfra lower opinion health marketweight
overweight lower recommend exposur
sector marketweight overweight group tradit
perform well tradit lacklust summer month keep
pace overal market remaind year besid alreadi
trade elev valuat particularli best perform
sub-industri medic technolog life scienc tool think
group contend increas political/regulatori risk
presidenti elect cycl get full swing final group
below-averag percentag favor constitu invest recommend
pm et cfra lift opinion share inc strong buy
buy cut target base
ep estim lower fy ep
fy ep post jun-q ep
vs line estim share declin
precipit today compani lower fy top-lin growth
guidanc rang prior rang
compani lower outlook primarili neg impact
confus fda letter regard impella rp system earlier
year origin thought could quickli overcom setback
short long-term investor expect see strength abmd
long-term potenti data present may show cardiogen patient
treat impella surviv rate vs cardiogen shock
patient without impella last year /kevin huang cfa
pm et cfra lift opinion share inc buy hold
lower target base
ep estim multipl low-end
three-year rang lower fy ep
initi fy ep post mar-q ep vs
equal estim sale rose mar-q million
consensu expect growth us impella product revenu
grew yoy believ us impella sale weak due
custom confus relat fda letter health care provid
februari regard increas mortal rate patient receiv
impella rp system unfortun health care provid media outlet
wrong interpret fda letter product recal hurt sale
divert manag attent subsequ clarifi increas
mortal rate specif salvag patient recoveri right
et cfra reiter hold opinion share inc
maintain target price above-p
ep estim multipl near averag
three-year rang keep ep
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
